AtriCure (NASDAQ:ATRC) Releases FY 2026 Earnings Guidance

AtriCure (NASDAQ:ATRC) updated its FY 2026 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 0.000-0.040 for the period, compared to the consensus estimate of 0.130. The company issued revenue guidance of $600.0 million-$610.0 million, compared to the consensus revenue estimate of $604.1 million.

Analyst Ratings Changes

Several analysts recently commented on the stock. Zacks Research downgraded shares of AtriCure from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AtriCure in a report on Monday, April 20th. Freedom Capital raised shares of AtriCure to a “strong-buy” rating in a report on Wednesday, April 1st. Needham & Company LLC reiterated a “buy” rating and issued a $45.00 price objective on shares of AtriCure in a research note on Thursday, February 12th. Finally, Oppenheimer cut shares of AtriCure from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 18th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $48.43.

AtriCure Stock Performance

AtriCure stock traded up $0.61 during midday trading on Tuesday, hitting $29.39. The company’s stock had a trading volume of 1,466,003 shares, compared to its average volume of 703,839. AtriCure has a 1-year low of $26.62 and a 1-year high of $43.18. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.96 and a quick ratio of 2.99. The company has a 50-day moving average price of $29.44 and a two-hundred day moving average price of $34.47. The company has a market cap of $1.49 billion, a price-to-earnings ratio of -122.46 and a beta of 1.28.

AtriCure (NASDAQ:ATRC) last issued its quarterly earnings data on Tuesday, February 17th. The medical device company reported $0.06 earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.10. AtriCure had a negative net margin of 2.14% and a negative return on equity of 1.15%. The business had revenue of $140.50 million during the quarter, compared to analysts’ expectations of $140.50 million. During the same quarter in the previous year, the company earned ($0.33) EPS. The business’s revenue was up 13.1% on a year-over-year basis. As a group, sell-side analysts predict that AtriCure will post 0.1 earnings per share for the current year.

Insiders Place Their Bets

In other AtriCure news, insider Vinayak Doraiswamy sold 5,000 shares of AtriCure stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $29.83, for a total value of $149,150.00. Following the completion of the sale, the insider owned 96,875 shares in the company, valued at $2,889,781.25. The trade was a 4.91% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 4.00% of the stock is owned by company insiders.

Hedge Funds Weigh In On AtriCure

Several hedge funds and other institutional investors have recently made changes to their positions in ATRC. Geneos Wealth Management Inc. acquired a new position in shares of AtriCure in the 2nd quarter valued at approximately $37,000. Smartleaf Asset Management LLC raised its position in shares of AtriCure by 59.8% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock valued at $46,000 after buying an additional 429 shares in the last quarter. State of Wyoming acquired a new position in shares of AtriCure in the 4th quarter valued at approximately $75,000. Kemnay Advisory Services Inc. acquired a new position in shares of AtriCure in the 4th quarter valued at approximately $114,000. Finally, Strs Ohio acquired a new position in shares of AtriCure in the 1st quarter valued at approximately $158,000. 99.11% of the stock is currently owned by institutional investors and hedge funds.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.